Kofituss Mucolitico

Carbocisteine, the active ingredient in Kofituss Mucolitico, is a mucolytic presented as an oral formulation for oral use. It helps reduce thick mucus in the airways of patients with chronic bronchitis, COPD and respiratory infections characterized by excessive sputum, and is marketed in the European Union.

GNH USA supplies Kofituss Mucolitico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Carbocisteine is used as a mucolytic agent to improve clearance of airway secretions in several respiratory conditions. - Chronic bronchitis: facilitates removal of thick sputum, improving cough efficiency. - Chronic obstructive pulmonary disease (COPD): reduces mucus viscosity, aiding breathing. - Respiratory tract infections with excessive mucus: helps clear secretions, supporting recovery.

Carbocisteine may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset. - Vomiting: occasional. - Diarrhea: loose stools. - Abdominal pain: cramp‑like discomfort. - Headache: transient. - Skin rash: mild erythema.

Serious or Rare Side Effects: - Allergic reactions: hives, swelling, or anaphylaxis. - Severe gastrointestinal bleeding: uncommon but possible. - Hepatotoxicity: rare liver enzyme elevation. - Blood dyscrasias: rare blood cell abnormalities.

When prescribing carbocisteine, several safety considerations should be observed. - Pregnancy: use only if clearly needed, as safety data are limited. - Breastfeeding: caution advised; monitor infant for adverse effects. - Renal impairment: dose adjustment may be required; assess kidney function. - Hepatic disease: monitor liver enzymes during therapy. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Carbocisteine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antitussives containing codeine: may reduce mucolytic effect. - Highly acidic antacids: can decrease carbocisteine absorption.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., beta‑agonists): monitor for additive respiratory effects. - Antibiotics (e.g., macrolides): observe for potential gastrointestinal synergy. - Anticoagulants (e.g., warfarin): watch for altered bleeding risk.